ArticleScientific reports2022
CRF07_BC is associated with slow HIV disease progression in Chinese patients.
Open access · goldAbstract read
In one paragraph
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.1field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 30 citations in OpenAlex.
- Characterization of drug resistance mutations in people living with HIV with low-level viremia on antiretroviral therapy in Chongqing, China.Frontiers in public health · 2026Article
- Characterization of transmitted drug resistance among recently infected HIV-1 men who have sex with men in Hebei Province, China.Scientific reports · 2025Article
- Article
- High genetic diversity of HIV-1 pol region and molecular transmission networks among people living with HIV-1 in Haikou, South China, 2005-2022.BMC infectious diseases · 2025Article
- Epidemiological and spatiotemporal analysis of elderly HIV-1/AIDS patients in Ningxia, China, from 2018 to 2023.Scientific reports · 2025Article
- Mortality and immunological indicators of men who have sex with men living with HIV on antiretroviral therapy: a 10-year retrospective cohort study in Southern China.BMC infectious diseases · 2025Article
- Effect of antiretroviral therapy on the mortality of HIV-1 infection long-term non-progressors: a cohort study.BMC infectious diseases · 2025Article
- The changing molecular epidemiology of HIV-1 in Liangshan prefecture, China, in 2021-2023.Frontiers in microbiology · 2025Article
- Identification of a Novel HIV-1 Recombinant Form Comprising CRF01_AE and Subtype C in Hebei Province, China.Current HIV research · 2025Article
- Genotypic Diversity and Pre-Treatment Resistance Characteristic Analysis Among Newly Diagnosed HIV-1-Positive MSM from 2020-2022 in Jiaxing City, China.Current HIV research · 2025Article
- Characterizing HIV-1 transmission by genetic cluster analysis among newly diagnosed patients in the China-Myanmar border region from 2020 to 2023.Emerging microbes & infections · 2024Article
- Article
- Characterization of an imported HIV-1 A1/A7/G recombinant in China.Virology journal · 2024Article
- How to report and make sense of a new HIV-1 circulating recombinant form?Frontiers in microbiology · 2024Article
- Epidemic trend, genetic characteristics, and transmission networks of HIV-1 among treatment-naive men who have sex with men in Hebei province, China.Frontiers in microbiology · 2024Article
- Immune reconstitution efficacy after combination antiretroviral therapy in male HIV-1 infected patients with homosexual and heterosexual transmission.Emerging microbes & infections · 2023Article
- Transmission network and phylogenetic analysis reveal older male-centered transmission of CRF01_AE and CRF07_BC in Guangxi, China.Emerging microbes & infections · 2023Article
- A New HIV-1 KMicrobiology spectrum · 2022Article
- Prevalence of resistance mutations associated with integrase inhibitors in therapy-naive HIV-positive patients in Baoding, Hebei province, China.Frontiers in genetics · 2022Article
- Unique profile of predominant CCR5-tropic in CRF07_BC HIV-1 infections and discovery of an unusual CXCR4-tropic strain.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
40 authors at 19 institutions in 1 country.
Jingrong YeInstitute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control (CDC) and Beijing Research Center for Preventive Medicine, No.16, Hepingli Middle Street; Dong Chen District, Beijing, China.
Jing ChenInstitute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control (CDC) and Beijing Research Center for Preventive Medicine, No.16, Hepingli Middle Street; Dong Chen District, Beijing, China.
Juan WangInstitute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control (CDC) and Beijing Research Center for Preventive Medicine, No.16, Hepingli Middle Street; Dong Chen District, Beijing, China.
Yuncong WangInstitute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control (CDC) and Beijing Research Center for Preventive Medicine, No.16, Hepingli Middle Street; Dong Chen District, Beijing, China.
Hui Xing *Division of Virology and Immunology, State Key Laboratory for Infectious Disease and Prevention and Control and National Center for AIDS/STD Prevention and Control (NCAIDS), China CDC, No.155 Changbai Road, Changping District, Beijing, China. xingh@chinaaids.cn.
Fengting YuClinical and Research Center of Infectious Diseases, Beijing DiTan Hospital, Capital Medical University, No. 8, Jingshun East Street, Chaoyang District, Beijing, China.
Lifeng LiuCenter for Infectious Diseases, Beijing YouAn Hospital, Capital Medical University, No. 8 of the Xitoutiao Outside the YouAnmen, Feng Tai District, Beijing, China.
Yang HanDepartment of Infectious Disease, Peking Union Medical College Hospital, No. 1, Wangfujing Shuaifuyuan, Beijing, China.
Huihuang HuangTreatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital of China, No.100 Western 4th Ring Middle Road, Fengtai District, Beijing, China.
Yi FengDivision of Virology and Immunology, State Key Laboratory for Infectious Disease and Prevention and Control and National Center for AIDS/STD Prevention and Control (NCAIDS), China CDC, No.155 Changbai Road, Changping District, Beijing, China.
Yuhua RuanDivision of Virology and Immunology, State Key Laboratory for Infectious Disease and Prevention and Control and National Center for AIDS/STD Prevention and Control (NCAIDS), China CDC, No.155 Changbai Road, Changping District, Beijing, China.
Minna ZhengInstitute for HIV/AIDS and STD Prevention and Control, Tianjin CDC, No. 6 Huayue Road, Hedong District, Tianjin, China.
Xinli LuInstitute for HIV/AIDS and STD Prevention and Control, Hebei CDC, No. 97 Huaian East Road, Shijiazhuang, Hebei, China.
Xiaoli GuoInstitute for HIV/AIDS and STD Prevention and Control, Shanxi CDC, No. 8 Xiaonanguan, Shuangta West Street, Yingze District, Taiyuan, Shanxi, China.
Hong YangInstitute for HIV/AIDS and STD Prevention and Control, Inner Mongolia CDC, No. 50 Erdos Street, Hohhot, Inner Mongolia, China.
Qi GuoInstitute for HIV/AIDS and STD Prevention and Control, Jilin CDC, No. 3145 Jingyang Road Changchun, Jilin, China.
Yi LinInstitute for HIV/AIDS and STD Prevention and Control, Shanghai CDC, No. 1380 Zhongshan West Road, Shanghai, China.
Jianjun WuInstitute for HIV/AIDS and STD Prevention and Control, Anhui CDC, No. 12560 Fanhua Road, Economic and Technological Development Zone, Hefei, Anhui, China.
Shouli WuInstitute for HIV/AIDS and STD Prevention and Control, Fujian CDC, No. 76 Jintai Road, Gulou District, Fuzhou, Fujian, China.
Yilong TangInstitute for HIV/AIDS and STD Prevention and Control, Jiangxi CDC, No. 555 Beijing East Road, Nanchang, Jiangxi, China.
Xiaoguang SunInstitute for HIV/AIDS and STD Prevention and Control, Shandong CDC, No. 16992 Jingshi Road, Jinan, Shandong, China.
Xiaobai ZouInstitute for HIV/AIDS and STD Prevention and Control, Hunan CDC, No. 450 Furong Middle Road, 1st Section, Changsha, Hunan, China.
Guolong YuInstitute for HIV/AIDS and STD Prevention and Control, Guangdong CDC, No. 160 Qunxian Road, Dashi Street, Panyu District, Guangzhou, Guangdong, China.
Jianjun LiInstitute for HIV/AIDS and STD Prevention and Control, Guangxi CDC, No. 18 Jinzhou Road Nanning, Guangxi, China.
Quanhua ZhouInstitute for HIV/AIDS and STD Prevention and Control, Chongqing CDC, No. 8 Yangtze 2nd Road, Yuzhong District, Chongqing, China.
Ling SuInstitute for HIV/AIDS and STD Prevention and Control, Sichuan CDC, No. 6 Middle School Road, Chengdu, Sichuan, China.
Lincai ZhangInstitute for HIV/AIDS and STD Prevention and Control, Gansu CDC, No. 310 Donggang West Road, Lanzhou, Gansu, China.
Zhan GaoBeijing Red Cross Blood Center, No. 37 North 3rd Ring Middle Road, Haidian District, Beijing, China.
Ruolei XinInstitute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control (CDC) and Beijing Research Center for Preventive Medicine, No.16, Hepingli Middle Street; Dong Chen District, Beijing, China.
Shufang HeInstitute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control (CDC) and Beijing Research Center for Preventive Medicine, No.16, Hepingli Middle Street; Dong Chen District, Beijing, China.
Conghui XuInstitute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control (CDC) and Beijing Research Center for Preventive Medicine, No.16, Hepingli Middle Street; Dong Chen District, Beijing, China.
Mingqiang HaoInstitute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control (CDC) and Beijing Research Center for Preventive Medicine, No.16, Hepingli Middle Street; Dong Chen District, Beijing, China.
Yinxiao HaoInstitute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control (CDC) and Beijing Research Center for Preventive Medicine, No.16, Hepingli Middle Street; Dong Chen District, Beijing, China.
Xianlong RenInstitute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control (CDC) and Beijing Research Center for Preventive Medicine, No.16, Hepingli Middle Street; Dong Chen District, Beijing, China.
Jie LiInstitute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control (CDC) and Beijing Research Center for Preventive Medicine, No.16, Hepingli Middle Street; Dong Chen District, Beijing, China.
Lishi BaiInstitute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control (CDC) and Beijing Research Center for Preventive Medicine, No.16, Hepingli Middle Street; Dong Chen District, Beijing, China.
Tianjun JiangTreatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital of China, No.100 Western 4th Ring Middle Road, Fengtai District, Beijing, China.
Tong ZhangCenter for Infectious Diseases, Beijing YouAn Hospital, Capital Medical University, No. 8 of the Xitoutiao Outside the YouAnmen, Feng Tai District, Beijing, China.
Yiming Shao *Division of Virology and Immunology, State Key Laboratory for Infectious Disease and Prevention and Control and National Center for AIDS/STD Prevention and Control (NCAIDS), China CDC, No.155 Changbai Road, Changping District, Beijing, China. yshao@bjmu.edu.cn.
Hongyan Lu *Institute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Prevention and Control (CDC) and Beijing Research Center for Preventive Medicine, No.16, Hepingli Middle Street; Dong Chen District, Beijing, China. hongyanlu1972@sina.com.
National Center for AIDS/STD Control and Prevention,China CDC · CNBeijing Center for Disease Prevention and Control · CNChinese PLA General Hospital · CNGuangxi Center for Disease Prevention and Control · CNAnhui Provincial Center for Disease Control and Prevention · CNBeijing Ditan Hospital · CNBeijing Red Cross Blood Center · CNBeijing YouAn Hospital · CNCapital Medical University · CNFujian Institute of Microbiology · CNGansu Provincial Center for Disease Control and Prevention · CNHebei Provincial Center for Disease Control and Prevention · CNHunan Provincial Center for Disease Control and Prevention · CNInner Mongolia Comprehensive Disease Prevention and Control Center · CNPeking Union Medical College Hospital · CNShandong Center for Disease Control and Prevention · CNShanghai Municipal Center For Disease Control Prevention · CNSichuan Center for Disease Control and Prevention · CNTianjin Centers for Disease Control and Prevention · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
HIV subtypes convey important epidemiological information and possibly influence the rate of disease progression. In this study, HIV disease progression in patients infected with CRF01_AE, CRF07_BC, and subtype B was compared in the largest HIV molecular epidemiology study ever done in China. A national data set of HIV pol sequences was assembled by pooling sequences from public databases and the Beijing HIV laboratory network. Logistic regression was used to assess factors associated with the risk of AIDS at diagnosis ([AIDSAD], defined as a CD4 count < 200 cells/µL) in patients with HIV subtype B, CRF01_AE, and CRF07_BC. Of the 20,663 sequences, 9,156 (44.3%) were CRF01_AE. CRF07_BC was responsible for 28.3% of infections, followed by B (13.9%). In multivariable analysis, the risk of AIDSAD differed significantly according to HIV subtype (OR for CRF07_BC vs. B: 0.46, 95% CI 0.39─0.53), age (OR for ≥ 65 years vs. < 18 years: 4.3 95% CI 1.81─11.8), and transmission risk groups (OR for men who have sex with men vs. heterosexuals: 0.67 95% CI 0.6─0.75). These findings suggest that HIV diversity in China is constantly evolving and gaining in complexity. CRF07_BC is less pathogenic than subtype B, while CRF01_AE is as pathogenic as B.
Indexed as
HIV-1HIV InfectionsSexual and Gender MinoritiesAgedChinaDisease ProgressionGenotypeHomosexuality, MaleHumansMalePhylogenySequence Analysis, DNA
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.